Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2

Clinical trial NCT07617753 · RECRUITING

Trial details

NCT number: NCT07617753
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Carcinoma Recurrent or Refractory Disease After Standard Therapies

Start date: 2026-03-02
Primary completion: 2027-06-14
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.